FBLG FibroBiologics, Inc.
NEUTRAL
Impact: 4/10
PRESS-RELEASE
Press release: fda
Latest settled — T+20d ⚠ clustered
FBLG ▼ -18.84% at T+20d
NEUTRAL call ✗ call lost -18.84% · α vs SPY -24.49% · entry $1.38 → $1.12
Last close $0.9310 (close Jun 12) · -32.54% from $1.38 entry
T+1d
-3.62%
call -3.62% · α -4.42%
$1.33
settled 6w ago
T+5d
-28.26%
call -28.26% · α -31.20%
$0.9900
settled 5w ago
T+20d
-18.84%
call -18.84% · α -24.49%
$1.12
settled 13d ago
T+60d
—
call — · α —
—
in 6w
Price Chart
Loading chart...
Executive Summary
FibroBiologics announced the release of the first cGMP batch of its CYWC628 drug product for a Phase 1/2 clinical trial in diabetic foot ulcers. This milestone enables patient enrollment but does not provide clinical data or financial impact.
Actionable Insight
Monitor the initiation of patient enrollment and any subsequent clinical data readouts. The small market cap ($8M) could lead to volatility on enrollment updates.
Key Facts
- First cGMP batch of CYWC628 released for Phase 1/2 DFU trial
- Drug product passed all safety and quality testing
- Patient enrollment to begin
Financial Impact
No financial figures provided in the release
Risk Factors
- Clinical trial failure or delays
- Need for additional capital to fund trials
- Regulatory and manufacturing risks
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286693 |
13 reports for FBLG
100%
Hit rate
best @ T+5▲ +32.22%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 11, 2026
4w ago
|
Press Release
| $0.9900 $1.09 | ▲ +10.10% | ▲ +10.19% | $0.9310 (−5.96%) |
|
May 5, 2026
5w ago
|
DEFA14A
| $1.33 $0.9900 | ▼ −25.56% | ▼ −27.55% | $0.9310 (−30.00%) |
|
May 4, 2026
5w ago
|
Press Release
| $1.33 $0.9900 | ▼ −25.56% | ▼ −27.55% | $0.9310 (−30.00%) |
|
May 4, 2026
5w ago
|
Press Release
| $1.38 $0.9900 | ▼ −28.26% | ▼ −31.20% | $0.9310 (−32.54%) |
|
Apr 30, 2026
6w ago
|
Press Release
| $1.46 $1.24 | ▼ −15.07% | ▼ −17.42% | $0.9310 (−36.23%) |
|
Apr 20, 2026
7w ago
|
8-K
| $1.52 $1.36 | ▼ −10.53% | ▼ −11.61% | $0.9310 (−38.75%) |
|
Apr 3, 2026
10w ago
|
8-K
| $1.37 $1.37 | · 0.00% | ▼ −4.13% | $0.9310 (−32.04%) |
|
Apr 1, 2026
10w ago
|
424B4
| $1.38 $1.35 | ▲ +2.17% | ▲ +5.79% | $0.9310 (+32.54%) |
|
Apr 1, 2026
10w ago
|
EFFECT
| $1.33 $1.38 | ▲ +3.76% | ▼ −0.01% | $0.9310 (−30.00%) |
|
Apr 1, 2026
10w ago
|
Press Release
| $1.33 $1.38 | ▼ −3.76% | ▲ +0.01% | $0.9310 (+30.00%) |
Showing 10 of 13
US Market Status
Market Closed — Opens in 5h 8m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access